Healthcare sector M&A deals surge 85% in H1FY23: Grant Thornton
A few high-value transactions played a significant role in driving the total transaction value from $1.2 billion in Q1 2023 to $4.4 billion in H1 2023
biocon biologics
July 2023
November 2022
June 2022
February 2022
December 2021
November 2021
July 2021
January 2021
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
Mix and match vaccines, says Kiran Mazumdar-Shaw
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
Biocon’s biosimilar biz tops $4 bn in valuation
Abu Dhabi-based sovereign wealth fund ADQ has picked up 1.80% stake in Biocon Biologics for $75 million; The company already raised $255 million from global marquee investors last year.
